Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035945 · ClinicalTrials.gov registry record · Phase 2
ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00035945 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals.
The verdict
NCT00035945, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
Purpose of this study is to evaluate the safety, tolerability, antiviral activity, and pharmacokinetic behavior of ISIS 14803 administered for up to 12 weeks by intravenous infusions in patients with chronic hepatitis C.
Interventions
- DRUG ISIS 14803
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-10-01 |
| Est. Completion | 2004-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035945
The ClinicalTrials.gov registry entry for NCT00035945 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ISIS 14803 is the first listed.
NCT00035945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035945 about?
NCT00035945 is a clinical study titled "ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections". Purpose of this study is to evaluate the safety, tolerability, antiviral activity, and pharmacokinetic behavior of ISIS 14803 administered for up to 12 weeks by intravenous infusions in patients with chronic hepatitis C.
What is the current status of trial NCT00035945?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-10-01. Estimated completion is 2004-05-01.
What interventions are being tested in trial NCT00035945?
The interventions under investigation include: ISIS 14803 (DRUG).
Who is sponsoring clinical trial NCT00035945?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.